- Home
- MDGL vs REG Comparison
MDGL vs REG Comparison
Compare MDGL & REG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MDGL | REG |
|---|---|---|
| Founded | 2011 | 1963 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.8B | 14.0B |
| IPO Year | 2005 | 1994 |
Fundamental Metrics
Financial Performance| Metric | MDGL | REG |
|---|---|---|
| Price | $519.09 | $76.51 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 15 |
| Target Price | ★ $674.45 | $80.07 |
| AVG Volume (30 Days) | 372.3K | ★ 1.3M |
| Earning Date | 05-06-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 3.80% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.46 |
| Revenue | $180,133,000.00 | ★ $1,553,524,000.00 |
| Revenue This Year | $58.39 | $3.04 |
| Revenue Next Year | $48.55 | $4.52 |
| P/E Ratio | ★ N/A | $166.09 |
| Revenue Growth | N/A | ★ 6.85 |
| 52 Week Low | $393.61 | $66.86 |
| 52 Week High | $615.00 | $83.66 |
Technical Indicators
Market Signals| Indicator | MDGL | REG |
|---|---|---|
| Relative Strength Index (RSI) | 50.90 | 38.99 |
| Support Level | $498.59 | $75.09 |
| Resistance Level | $545.13 | $77.39 |
| Average True Range (ATR) | 19.22 | 1.22 |
| MACD | 1.86 | -0.16 |
| Stochastic Oscillator | 76.90 | 24.71 |
Price Performance
Historical ComparisonAbout MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.
About REG Regency Centers Corporation
Regency Centers is one of the largest shopping center-focused retail REITs. The company's portfolio includes an interest in 481 properties, which includes over 58 million square feet of retail space following the completion of the Urstadt Biddle acquisition in August 2023. The portfolio is geographically diversified with 22 regional offices and no single market representing more than 12% of total company net operating income. Regency's retail portfolio is primarily composed of grocery-anchored centers, with 80% of properties featuring a grocery anchor and grocery stores representing 20% of annual base rent.